Disclaimer

<script async src=”//pagead2.googlesyndication.com/pagead/js/adsbygoogle.js”></script>
<!– WVC –>
<ins class=”adsbygoogle”
style=”display:block”
data-ad-client=”ca-pub-6449009505407363″
data-ad-slot=”8608630732″
data-ad-format=”auto”></ins>
<script>
(adsbygoogle = window.adsbygoogle || []).push({});
</script>

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. 

The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.Our website and newsletter are for Entertainment purposes only.  This newsletter is NOT a source of unbiased information.  Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold The Wealthy Biotech Trader, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The Wealthy Biotech Trader sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by The Wealthy Biotech Trader or an offer or solicitation to buy or sell any security.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead The Wealthy Biotech Trader strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. The Wealthy Biotech Trader further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

COMPENSATION:  The Wealthy Biotech Trader’s parent company is engaged in a 6 month, $25,000 per month investor relations contract withPositiveID Corp. (OTC: PSID). The Wealthy Biotech Trader’s controlling parent company has also been compensated $62,500 by the Company in the form of a convertible note and readers should understand that we will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The Wealthy Biotech Trader’s parent company is engaged in a month to month, $5,000 per month investor relations contract with Propanc Health Group (OTC: PPCH). The Wealthy Biotech Trader’s controlling parent company has also been compensated $60,000 by the company in the form of a convertible note and readers should understand that we will convert this note into common shares sellthem into the market as soon as the statutory 144 hold period has lapsed.The Wealthy Biotech Trader’s parent company as hired to write and release a advertisement profile on Fast Funds Financial Corp.by Buy It Corp. for $500 This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The Wealthy Venture Capitalist’s parent company has been compensated $25,000 for a 1 month investor relations contract by QED Connect, Inc. QED Connect, Inc. has the option after 1 month to continue the services on a month to month basis. The wealthy venture capitalist’s parent company has been compensated $25,000 per month in a three month investor relations contract by Wisdom Homes Inc. The Wealthy Venture Capitalist’s parent company has also been compensated in the form of a convertible note for $65,000 by Wisdom Homes Inc. which will be converted into shares and sold when the hold period has lapsed. The Wealthy Venture Capitalist’s parent company has been compensated roughly $50,000 per month for 6 months by Directview Holdings Inc. The Wealthy Venture Capitalist’s controlling parent company has also been compensated $100,000 by Directview Holdings Inc. in the form of a convertible promissory note, and readers should understand that they will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed.The Wealthy Venture Capitalist’s parent company has been compensated roughly $50,000 per month for 3 months by IEG Holdings Corp. The Wealthy Venture Capitalist’s parent company has been compensated roughly $10,000 per month for 6 months by Propanc Health Group for investor relations services. The Wealthy Venture Capitalist’s controlling parent company has also been compensated 4,000,000 restricted shares and readers should understand that we will sell them into the market as soon as the statutory 144 hold period has lapsed.Wealthy Venture Capitalist’s parent company has been compensated roughly $10,000 per month for 6 months by PositiveID Corp for investor relations services. The Wealthy Venture Capitalist’s controlling parent company has also been compensated $62,500 by the PositiveID Corp in the form of a convertible note and readers should understand that we will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. Wealthy Venture Capitalist’s controlling parent company has also been compensated $150,000 by Endonovo Therapeutics, Inc. in the form of a convertible note and readers should understand that we will convert this note into common shares and sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Biotech Trader’s parent company was compensated $50,000 as well as 100,000 restricted preferred shares by Advanced Medical Isotope Corporation. Wealthy Biotech Trader has since renewed their contract with Advance Medical Isotope for 6 months for either 40,000 restricted common shares per month or $20,000 per month, at the discretion of The Wealthy Biotech Trader’s parent company. Readers should understand that we will sell them into the market as soon as the statutory 144 hold period has lapsed. The Wealthy Venture Capitalist’s controlling parent company has been compensated $15,000 per month by 22nd Century Group, Inc. for 12 months of marketing services. The Wealthy Venture Capitalist’s controlling parent company has since renewed their contract for an additional year for $4,200 per month paid in advance for marketing services. 

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage.

The Wealthy Venture Capitalist is a media and marketing outlet which consists of several sector-focused outlets collectively referred to as the Wealth Series: The Wealthy Biotech Trader, The Silicon Valley Insider and the Radical Consumerist (other may be added in the future). All of these outlets are named as “pen names” for the parent Company that owns and controls them, Circadian Group.

In preparing this publication, The Wealthy Biotech Trader has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, The Wealthy Biotech Trader and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. The Wealthy Biotech Trader is not responsible for any claims made by the companies advertised herein, nor is The Wealthy Biotech Trader responsible for any other promotional firm, its program or its structure.

 

 

About Us

The Wealthy Venture capitalist is a series of industry-focused Investment articles focused on showing everyday Investors new opportunities in rapidly growing, little-known stocks in 4 of the markets hottest sectors: Biotech, Technology, Medical and Recreational Marijuana, and Consumer products.

Distribution Policy

Comprehensive Report Distribution – Syndicated news stories are routed to many major outlets

Report Publication Announcements (press releases) – Report publication announcements are systematically made to the global financial community via press releases, which further lead to news coverage through additional, global journalistic channels.

Global Research Visibility – Powered by WVC’s strategic partnerships with companies around the world, our news stories receive unprecedented domestic and international exposure.



Wealthy Venture Capitalist